Literature DB >> 9949386

Phenotypic and genotypic heterogeneity in familial Milroy lymphedema.

M H Witte1, R Erickson, M Bernas, M Andrade, F Reiser, W Conlon, H E Hoyme, C L Witte.   

Abstract

Familial Milroy lymphedema (ML) is classified as an autosomal dominant disorder characterized by peripheral edema of the lower extremities at birth or in early childhood. The variety of phenotypes are not well described, and the genomic location and functional expression of the gene or genes underlying this and related familial lymphedema syndromes remain largely unknown. In this collaborative study between the University of Arizona and the University of São Paulo, we collected clinical pedigrees on 6 ML families, carried out clinical examination of affected and unaffected individuals, and, in representative affected members of two of the families performed dynamic lymphangioscintigraphy (LAS) of the lower and upper limbs to delineate further the ML lymphangiodysplastic phenotype. To localize the gene for ML, we conducted a genome-wide search in 4 of the families using 387 polymorphic dinucleotide-repeat markers at approximate 10 cM spacing in 54 subjects (affected, unaffected bloodline relatives, and spouses). In all 6 families (86 subjects), we specifically examined the suggested linkage to the vascular endothelial growth factor (VEGF)-C receptor (Flt4) gene localized to the chromosome region 5q34-q35. The findings provide evidence for a spectrum of ML clinical and LAS phenotypes and also suggest ML locus heterogeneity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9949386

Source DB:  PubMed          Journal:  Lymphology        ISSN: 0024-7766            Impact factor:   1.286


  12 in total

Review 1.  Gene and protein therapies utilizing VEGF for ALS.

Authors:  Orion P Keifer; Deirdre M O'Connor; Nicholas M Boulis
Journal:  Pharmacol Ther       Date:  2013-10-29       Impact factor: 12.310

2.  A five generation family with a novel mutation in FOXC2 and lymphedema worsening to hydrops in the youngest generation.

Authors:  Carole Sargent; Julien Bauer; Muhamed Khalil; Parker Filmore; Michael Bernas; Marlys Witte; M Peggy Pearson; Robert P Erickson
Journal:  Am J Med Genet A       Date:  2014-09-22       Impact factor: 2.802

3.  A model for gene therapy of human hereditary lymphedema.

Authors:  M J Karkkainen; A Saaristo; L Jussila; K A Karila; E C Lawrence; K Pajusola; H Bueler; A Eichmann; R Kauppinen; M I Kettunen; S Yla-Herttuala; D N Finegold; R E Ferrell; K Alitalo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-09       Impact factor: 11.205

Review 4.  A review of clinical trials of anti-VEGF agents for diabetic retinopathy.

Authors:  Benjamin P Nicholson; Andrew P Schachat
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-20       Impact factor: 3.117

5.  Wide clinical spectrum in a family with hereditary lymphedema type I due to a novel missense mutation in VEGFR3.

Authors:  Ronen Spiegel; Arash Ghalamkarpour; Etty Daniel-Spiegel; Miikka Vikkula; Stavit A Shalev
Journal:  J Hum Genet       Date:  2006-08-19       Impact factor: 3.172

6.  Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q.

Authors:  L N Bull; E Roche; E J Song; J Pedersen; A S Knisely; C B van Der Hagen; K Eiklid; O Aagenaes; N B Freimer
Journal:  Am J Hum Genet       Date:  2000-08-30       Impact factor: 11.025

7.  Digenic Inheritance of a FOXC2 Mutation and Two PIEZO1 Mutations Underlies Congenital Lymphedema in a Multigeneration Family.

Authors:  Debbie J Mustacich; Li-Wen Lai; Michael J Bernas; Jazmine A Jones; Reginald J Myles; Phillip H Kuo; Walter H Williams; Charles L Witte; Robert P Erickson; Marlys Hearst Witte
Journal:  Am J Med       Date:  2021-10-15       Impact factor: 4.965

8.  Analysis of the coding regions of VEGFR3 and VEGFC in Milroy disease and other primary lymphoedemas.

Authors:  F C Connell; P Ostergaard; C Carver; G Brice; N Williams; S Mansour; P S Mortimer; Steve Jeffery
Journal:  Hum Genet       Date:  2008-11-12       Impact factor: 4.132

9.  Experimental assessment of pro-lymphangiogenic growth factors in the treatment of post-surgical lymphedema following lymphadenectomy.

Authors:  Amy Baker; Harold Kim; John L Semple; Dan Dumont; Molly Shoichet; Dalia Tobbia; Miles Johnston
Journal:  Breast Cancer Res       Date:  2010-09-08       Impact factor: 6.466

10.  Vascular endothelial growth factor receptor-2 promotes the development of the lymphatic vasculature.

Authors:  Michael T Dellinger; Stryder M Meadows; Katherine Wynne; Ondine Cleaver; Rolf A Brekken
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.